A detailed history of Dafna Capital Management LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Dafna Capital Management LLC holds 80,972 shares of ASND stock, worth $11.7 Million. This represents 2.83% of its overall portfolio holdings.

Number of Shares
80,972
Previous 92,472 12.44%
Holding current value
$11.7 Million
Previous $14 Million 21.0%
% of portfolio
2.83%
Previous 3.37%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$121.07 - $153.67 $1.39 Million - $1.77 Million
-11,500 Reduced 12.44%
80,972 $11 Million
Q1 2024

May 15, 2024

SELL
$123.45 - $159.4 $3.83 Million - $4.94 Million
-31,000 Reduced 25.11%
92,472 $14 Million
Q4 2023

Feb 14, 2024

SELL
$86.1 - $127.36 $1.1 Million - $1.62 Million
-12,740 Reduced 9.35%
123,472 $15.6 Million
Q3 2023

Nov 14, 2023

BUY
$86.5 - $103.97 $86,500 - $103,970
1,000 Added 0.74%
136,212 $12.8 Million
Q1 2023

May 15, 2023

BUY
$104.9 - $126.78 $524,500 - $633,900
5,000 Added 3.84%
135,212 $14.5 Million
Q4 2022

Feb 14, 2023

SELL
$99.42 - $131.97 $546,810 - $725,835
-5,500 Reduced 4.05%
130,212 $15.9 Million
Q3 2022

Nov 14, 2022

SELL
$84.03 - $110.23 $294,105 - $385,805
-3,500 Reduced 2.51%
135,712 $14 Million
Q2 2022

Aug 15, 2022

BUY
$78.08 - $117.61 $8.48 Million - $12.8 Million
108,600 Added 354.76%
139,212 $12.9 Million
Q1 2022

May 16, 2022

BUY
$102.18 - $135.75 $2 Million - $2.66 Million
19,612 Added 178.29%
30,612 $3.59 Million
Q4 2021

Feb 14, 2022

BUY
$127.1 - $169.66 $1.4 Million - $1.87 Million
11,000 New
11,000 $1.48 Million
Q3 2021

Nov 15, 2021

SELL
$112.67 - $176.92 $804,125 - $1.26 Million
-7,137 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$121.62 - $145.29 $1.96 Million - $2.34 Million
-16,100 Reduced 69.29%
7,137 $939,000
Q4 2020

Feb 16, 2021

SELL
$151.2 - $182.76 $907,199 - $1.1 Million
-6,000 Reduced 20.52%
23,237 $3.88 Million
Q3 2020

Nov 16, 2020

BUY
$134.29 - $154.32 $2.01 Million - $2.31 Million
15,000 Added 105.36%
29,237 $4.51 Million
Q2 2020

Aug 14, 2020

SELL
$110.87 - $156.01 $2.16 Million - $3.04 Million
-19,500 Reduced 57.8%
14,237 $2.11 Million
Q1 2020

May 15, 2020

BUY
$97.01 - $145.11 $546,845 - $817,985
5,637 Added 20.06%
33,737 $3.8 Million
Q4 2019

Feb 14, 2020

SELL
$91.45 - $139.12 $2.96 Million - $4.5 Million
-32,380 Reduced 53.54%
28,100 $3.91 Million
Q3 2019

Nov 14, 2019

BUY
$95.8 - $118.9 $105,380 - $130,790
1,100 Added 1.85%
60,480 $5.83 Million
Q2 2019

Aug 14, 2019

BUY
$107.11 - $132.09 $1.61 Million - $1.98 Million
15,000 Added 33.8%
59,380 $6.84 Million
Q1 2019

May 15, 2019

SELL
$62.15 - $129.99 $2.04 Million - $4.27 Million
-32,862 Reduced 42.54%
44,380 $5.22 Million
Q3 2018

Nov 14, 2018

BUY
$63.77 - $76.28 $223,003 - $266,751
3,497 Added 4.74%
77,242 $5.47 Million
Q2 2018

Aug 13, 2018

SELL
$58.55 - $73.92 $322,025 - $406,560
-5,500 Reduced 6.94%
73,745 $4.91 Million
Q1 2018

May 15, 2018

SELL
$38.98 - $68.04 $1.77 Million - $3.09 Million
-45,394 Reduced 36.42%
79,245 $5.18 Million
Q4 2017

Feb 14, 2018

BUY
$31.98 - $40.38 $1.68 Million - $2.12 Million
52,413 Added 72.57%
124,639 $4.99 Million
Q3 2017

Nov 14, 2017

BUY
$26.89 - $37.1 $1.94 Million - $2.68 Million
72,226
72,226 $2.62 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $8.07B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.